Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U. Lin, Eric P. Winer, Elisavet Paplomata et al.|Journal of Clinical Oncology|2020Cited by 556
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).Nancy U. Lin, Eric P. Winer, Rashmi K. Murthy et al.|Journal of Clinical Oncology|2020Cited by 12